Clinical Trial Update: A Phase Ⅲ Comparative Study of QL2108 to Dupixent® [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial update comparing QL2108 to Dupixent for atopic dermatitis. The study is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• DUPIXENT (DUPILUMAB)
• QL2108

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Atopic Dermatitis | Phase 3 | Status: NOT_YET_RECRUITING